Longitudinal risk factors for obstructive sleep apnea: A systematic review
- PMID: 37639973
- DOI: 10.1016/j.smrv.2023.101838
Longitudinal risk factors for obstructive sleep apnea: A systematic review
Abstract
Despite substantial disease burden, existing evidence on the risk factors for obstructive sleep apnea (OSA) have been derived primarily from cross-sectional studies without determining temporality. Therefore, we aimed to systematically synthesize the literature on longitudinal risk factors for sleep study-assessed OSA and questionnaire-assessed probable OSA from cohort studies in the general adult population settings. We systematically searched Embase and Medline (on OVID) databases. Eleven studies met the inclusion criteria. Meta-analyses were not conducted due to methodological heterogeneity of exposure and outcome measurements. There was consistent evidence that weight gain was associated with incident (n = 2) and greater severity (n = 2) of OSA. One study each observed an association of higher baseline body-mass index, male sex, asthma, a specific genetic polymorphism in rs12415421, and insulin resistance/hyperglycemia, with incident OSA. Long-term exposure to ambient air pollution (NO2, n = 1) was associated with OSA, and menopausal transitions (n = 1) with higher apnea-hypopnea index. There were no eligible studies on long-term smoking or alcohol use. In conclusion, approximately 10% increase in weight, especially in males, might alert clinicians to consider potential or worsening OSA. Large, well-designed longitudinal studies are needed to consolidate knowledge on other associations with OSA development, especially on potentially modifiable risk factors.
Keywords: Cohort; General population; Longitudinal studies; Obstructive sleep apnea; Risk factors; Systematic review.
Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Declaration of competing interest G.S.H has received equipment to support research from ResMed and Air Liquide Healthcare. S.C.D., C.J.L., J.L.P and A.J.L. declare they have received research funds from GSK's competitively awarded Investigator Sponsored Studies program, for unrelated research. A.J.L & S.C.D have received grant funding from SanofiRegeneron for unrelated research. A.J.L. has also received donations of interventional product (EpiCeram) from Primus Pharmaceuticals for unrelated research.
Publication types
LinkOut - more resources
Full Text Sources
Miscellaneous